Kuros N/ CH0325814116 /
05/08/2024 16:18:34 | Chg. -1.540 | Volume | Bid16:19:00 | Ask16:19:00 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
11.460CHF | -11.85% | 560,139 Turnover: 6.38 mill. |
11.420Bid Size: 79 | 11.480Ask Size: 200 | 425.57 mill.CHF | - | - |
GlobeNewswire
03/02/2022
Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications
GlobeNewswire
28/09/2021
Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting
GlobeNewswire
15/07/2021
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royal...
GlobeNewswire
15/07/2021
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Bioscie...
GlobeNewswire
02/03/2021
Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe
GlobeNewswire
09/09/2020
CORRECTING AND REPLACING -- Kuros Biosciences’s Licensee Checkmate Pharmaceuticals Completes its IPO...
GlobeNewswire
09/09/2020
Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ
GlobeNewswire
01/09/2020
Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PT...
GlobeNewswire
30/01/2020
Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superiority to Market-Leading S...
GlobeNewswire
02/10/2019
Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advan...
GlobeNewswire
24/09/2019
Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North Americ...
GlobeNewswire
03/09/2019
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Cli...
GlobeNewswire
09/07/2019
Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia...
GlobeNewswire
30/04/2019
Kuros Biosciences to Propose Re-Appointment of Chairman and Board Members at Annual General Meeting
GlobeNewswire
09/04/2019
Kuros Biosciences Enters Convertible Bond Financing Agreement For Up To CHF 5 Million